Suchergebnisse - "Jackson, Akil"

PubPharm (58)

1

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals

enthalten in: HIV clinical trials | 2018

von Jackson, A. | Else, L. | Higgs, C. | +6

2

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

Erschienen: 2017

von Nyombayire, J. | Anzala, O. | Gazzard, B. | +24

3

An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers

enthalten in: Antiviral therapy | 2017

von Randell, P. | Jackson, A. | Milinkovic, A. | +2

4

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine : Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

enthalten in: The Journal of infectious diseases | 2017

von Nyombayire, J. | Anzala, O. | Gazzard, B. | +44

5

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

enthalten in: The journal of infectious diseases | 2017

von Nyombayire, J. | Anzala, O. | Gazzard, B. | +24

6

Brief Report : Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2016

von Fox, J. | Tiraboschi, J. | Herrera, C. | +9

7

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

enthalten in: The Journal of antimicrobial chemotherapy | 2016

von Elliot, E. | Amara, A. | Jackson, A. | +6

8

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

enthalten in: The Journal of infectious diseases | 2016

von Penrose, K. | Parikh, U. | Hamanishi, K. | +5

9

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

Erschienen: 2016

von Penrose, K. | Parikh, U. | Hamanishi, K. | +5

10

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

enthalten in: The journal of infectious diseases | 2016

von Penrose, K. | Parikh, U. | Hamanishi, K. | +5

1
2
3
4
5
6
Nächster »
[6]